Facinicline HCl | RG3487 | CAS#677305-02-1

MedKoo Cat#: 525889 | Name: Facinicline HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Facinicline, also known as RG-3487, R-3487 or MEM-3454, is a partial agonist of the nicotinic alpha-7 (α7) receptor that was being co-developed by Roche for the oral treatment of Alzheimer's.

Chemical Structure

Facinicline HCl

CAS#677305-02-1(HCl)

Theoretical Analysis

MedKoo Cat#: 525889

Name: Facinicline HCl

CAS#: 677305-02-1(HCl)

Chemical Formula: C15H19ClN4O

Exact Mass: 306.1247

Molecular Weight: 306.79

Elemental Analysis: C, 58.73; H, 6.24; Cl, 11.55; N, 18.26; O, 5.21

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

677306-35-3 (free base) 677305-02-1(HCl)

Synonym

Facinicline HCl, Facinicline hydrochloride; RG-3487; RG 3487; RG3487; R-3487; R 3487; R3487; RO-5313534; RO 5313534; RO5313534; MEM3454; MEM 3454; MEM-3454;

IUPAC/Chemical Name

N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1H-indazole-3-carboxamide hydrochloride

InChi Key

CMRLNEYJEPELSM-BTQNPOSSSA-N

InChi Code

InChI=1S/C15H18N4O.ClH/c20-15(14-11-3-1-2-4-12(11)17-18-14)16-13-9-19-7-5-10(13)6-8-19;/h1-4,10,13H,5-9H2,(H,16,20)(H,17,18);1H/t13-;/m1./s1

SMILES Code

O=C(C1=NNC2=C1C=CC=C2)N[C@@H]3CN4CCC3CC4.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 306.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Boess F, Lenz B, Funk J, Niederhauser U, Bassett S, Zhang JD, Singer T, Roth AB. Use of early phenotypic in vivo markers to assess human relevance of an unusual rodent non-genotoxic carcinogen in vitro. Toxicology. 2017 Mar 15;379:48-61. doi: 10.1016/j.tox.2017.01.018. Epub 2017 Feb 5. PubMed PMID: 28174063. 2: Kuang S, Zhang P, Dong EZ, Jennings G, Zhao B, Pierce M. Crystal form control and particle size control of RG3487, a nicotinic α7 receptor partial agonist. Int J Pharm. 2016 Jul 11;508(1-2):109-22. doi: 10.1016/j.ijpharm.2016.04.066. Epub 2016 May 7. PubMed PMID: 27167333. 3: Hashimoto K. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker. Curr Pharm Des. 2015;21(26):3797-806. Review. PubMed PMID: 26044974; PubMed Central PMCID: PMC5024727. 4: Hao Y, Tang J, Wang K. Development of Automated Patch Clamp Assay for Evaluation of α7 Nicotinic Acetylcholine Receptor Agonists in Automated QPatch-16. Assay Drug Dev Technol. 2015 Apr;13(3):174-84. doi: 10.1089/adt.2014.622. Epub 2015 Apr 16. PubMed PMID: 25880723. 5: Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2014 Jun;39(7):1568-77. doi: 10.1038/npp.2014.17. Epub 2014 Jan 27. PubMed PMID: 24549101; PubMed Central PMCID: PMC4023143. 6: Huang M, Felix AR, Kwon S, Lowe D, Wallace T, Santarelli L, Meltzer HY. The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. Psychopharmacology (Berl). 2014 May;231(10):2199-210. doi: 10.1007/s00213-013-3373-5. Epub 2013 Dec 7. PubMed PMID: 24317442. 7: Pohanka M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci. 2012;13(2):2219-38. doi: 10.3390/ijms13022219. Epub 2012 Feb 17. Review. PubMed PMID: 22408449; PubMed Central PMCID: PMC3292018. 8: Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, Xie W, Rowe WB, Ong V, Graham E, Terry AV Jr, Rodefer JS, Herbert B, Murray M, Porter R, Santarelli L, Lowe DA. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther. 2011 Jan;336(1):242-53. doi: 10.1124/jpet.110.171892. Epub 2010 Oct 19. PubMed PMID: 20959364.